Neonatal abstinence syndrome (NAS) is a withdrawal syndrome primarily occurring in infants with in utero exposure to opioids. Neonatal abstinence syndrome is an important indicator of the immediate effect of the opioid crisis. Little is known about the physical and developmental health consequences of prenatal opioid exposure.1 Neonatal abstinence syndrome incidence rates have increased from 1.5 to 8.0 per 1000 hospital births in the United States from 2004 to 2014.2 Total hospital costs reached $316 million in 2012 and accounted for 4% of all neonatal intensive care unit hospital days nationwide in 2013.3,4 This study provides new national incidence and cost estimates for NAS in 2016.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Strahan AE, Guy GP, Bohm M, Frey M, Ko JY. Neonatal Abstinence Syndrome Incidence and Health Care Costs in the United States, 2016. JAMA Pediatr. 2020;174(2):200–202. doi:10.1001/jamapediatrics.2019.4791
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: